Clinical trial
Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy…
NCT00492063 · Novartis Vaccines, Industry · Completed
Key facts
| NCT number | NCT00492063 |
|---|---|
| Title | Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly |
| Official title | A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture and of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in… |
| Lead sponsor | Novartis Vaccines, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Cell culture-derived trivalent subunit influenza vaccine (cTIV), Egg-derived trivalent subunit influenza vaccine (TIV) |
| Enrollment | 2,654 |
| Start date | Sep 1, 2004 |
| Primary completion | Dec 1, 2004 |
| Completion | May 1, 2005 |
| First posted | Jun 27, 2007 |
| Last update posted | Jan 1, 2016 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: